American Diversified Holdings Corporation Receives $5,000,000 (Five Million) Financing Commitment from an Institutional Investment Fund

Investment Commitment - A prominent institutional investment fund has committed to providing up to $5,000,000 in financing to American Diversified Holdings Corporation (ADHC) [1][2] Use of Funds - The investment proceeds are designated for the research and development of the GlucoGuard project and for general corporate purposes, as well as to support collaboration with DexCom, a Continuous Glucose Monitoring (CGM) development partner [2] FDA Interaction - ADHC has engaged with its Medical Advisory Board and the FDA, leading to a request for a two-prong sleep study to address safety and efficacy concerns regarding the GlucoGuard device [3] FDA Review - The major components of the Breakthrough Device Application Designation have received positive feedback from the FDA regarding the unmet need and GlucoGuard's potential to assist patients [4] Company Mission - The investment is expected to enhance ADHC's valuation and support its mission to help Type 1 Diabetics manage hypoglycemic events, thereby improving patients' lives [5]